Silence Therapeutics Appoints New Vice President of Research
Move Bolsters Scientific Team at Company's Research Center in Berlin
Silence Therapeutics plc announced the promotion of Jorg Kaufmann, Ph.D., to the position of vice president of research. In this new position, Dr. Kaufmann, who previously served as senior director, technologies at Silence, will play a key role in overseeing the Company's range of RNA interference (RNAi) research activities, including those focused on advancing Silence's novel small interfering RNA (siRNA) delivery technologies. Dr. Kaufmann will continue to be based at Silence's Berlin research center, where the Company is consolidating all research activities related to its novel RNAi therapeutic platforms.
Dr. Kaufmann possesses more than 13 years of biotechnology industry experience in both the United States and Europe. Since joining Silence in 2000, he has served as both senior and associate director, technologies at the Company's Berlin location. Prior to joining Silence, Dr. Kaufmann was a senior scientist at Chiron Corporation, where he was responsible for leading one of the company's molecular biology research groups focused on breast cancer. From 1996-1997 he served as a group leader at the Institute of Tumour Biology (IMT) in Marburg,Germany. Dr. Kaufmann was a postdoctoral fellow at the Howard Hughes Medical Institute,University of California, Los Angelesand received his Ph.D. in molecular biology from the Philipps University Marburg.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
